PTPN2/N1 are thus emerging as intracellular checkpoints curbing T-cell-mediated antitumor immunity [107], positioning PTPN2/N1-targeted therapy at the crux of a dual anti-cancer strategy by directly attacking tumor cells and fortifying the antitumor efficacy of immune cells. Here, PTPN2 is linked to neoplasm.